Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fate Therapeutics (FATE) Interest & Investment Income (2016 - 2025)

Fate Therapeutics (FATE) has disclosed Interest & Investment Income for 13 consecutive years, with $2.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Interest & Investment Income fell 42.69% year-over-year to $2.2 million, compared with a TTM value of $11.1 million through Dec 2025, down 36.07%, and an annual FY2025 reading of $11.1 million, down 36.07% over the prior year.
  • Interest & Investment Income was $2.2 million for Q4 2025 at Fate Therapeutics, down from $2.6 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $4.8 million in Q2 2024 and bottomed at $289000.0 in Q3 2021.
  • Average Interest & Investment Income over 5 years is $2.6 million, with a median of $2.9 million recorded in 2022.
  • The sharpest move saw Interest & Investment Income crashed 61.21% in 2021, then surged 869.7% in 2022.
  • Year by year, Interest & Investment Income stood at $297000.0 in 2021, then soared by 869.7% to $2.9 million in 2022, then skyrocketed by 53.26% to $4.4 million in 2023, then dropped by 12.23% to $3.9 million in 2024, then plummeted by 42.69% to $2.2 million in 2025.
  • Business Quant data shows Interest & Investment Income for FATE at $2.2 million in Q4 2025, $2.6 million in Q3 2025, and $2.9 million in Q2 2025.